NP1192

NP1192 is a potent and selective PROTAC NAT10 degrader that reduces NAT10 protein expression in cancer cells and inhibits ac4C modification. It disrupts the NAT10/HIF-1α/PD-L1 axis, leading to dual suppression of hypoxia-driven glycolysis and immunosuppression, demonstrating significant antitumor efficacy both in vitro and in vivo, and producing synergistic effects when combined with anti-PD-L1 treatment. NP1192 is applicable for research in ovarian cancer, cervical cancer, and glioblastoma.